Adaptimmune Therapeutics has signed a strategic partnership and licence agreement with Roche Group member, Genentech, to develop and market allogeneic cell therapies for the treatment of multiple cancer indications.

The partnership involves creating allogeneic T-cell therapies for up to five shared cancer targets and the development of customised allogeneic T-cell therapies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Adaptimmune will develop clinical candidates leveraging its induced pluripotent stem cell (iPSC)-obtained allogeneic platform to create T-cells (iT cells) for each component.

Genentech will oversee the input TCRs and subsequent clinical development and marketing.

As per the deal, Adaptimmune is eligible for $150m in upfront payment from Genentech and further payments of $150m over five years, unless the deal is terminated before this term.

Furthermore, Adaptimmune will get potential research, development, regulatory as well as commercial milestone payments of over $3bn in total.

Genentech will also make tiered mid-single to low-double-digit royalty payments based on net product sales to Adaptimmune.

In addition, Adaptimmune holds an option to equally share profit and costs of the off-the-shelf products in the US.

On Adaptimmune opting in, the company will require to share half of the profits and losses from US sales on such products.

The company will also get regulatory, sales-based milestone and royalty payments on net sales outside the US region.

Roche Pharma Partnering global head James Sabry said: “We believe allogeneic cell therapies could be a game-changing approach for developing personalised therapy platforms based on individual cancer patients’ unique needs.

“This partnership, which combines Adaptimmune’s allogeneic platform with Genentech’s expertise in developing personalised therapies, complements our other efforts to discover and develop personalised cell therapies.”

In May, Genentech and Pieris Pharmaceuticals signed a multi-programme research partnership and licence agreement worth approximately $1.42bn to discover, develop and market respiratory and ophthalmology therapies.